Zevra Therapeutics (ZVRA) Equity Average (2016 - 2025)
Historic Equity Average for Zevra Therapeutics (ZVRA) over the last 10 years, with Q3 2025 value amounting to $125.2 million.
- Zevra Therapeutics' Equity Average rose 14488.99% to $125.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $125.2 million, marking a year-over-year increase of 14488.99%. This contributed to the annual value of $50.8 million for FY2024, which is 2588.19% down from last year.
- As of Q3 2025, Zevra Therapeutics' Equity Average stood at $125.2 million, which was up 14488.99% from $79.1 million recorded in Q2 2025.
- Zevra Therapeutics' Equity Average's 5-year high stood at $438.4 million during Q2 2023, with a 5-year trough of $8.9 million in Q1 2021.
- Moreover, its 5-year median value for Equity Average was $125.2 million (2025), whereas its average is $170.2 million.
- Per our database at Business Quant, Zevra Therapeutics' Equity Average skyrocketed by 303645.94% in 2022 and then crashed by 9072.87% in 2024.
- Over the past 5 years, Zevra Therapeutics' Equity Average (Quarter) stood at $129.4 million in 2021, then skyrocketed by 97.12% to $255.1 million in 2022, then tumbled by 75.82% to $61.7 million in 2023, then dropped by 11.31% to $54.7 million in 2024, then surged by 128.8% to $125.2 million in 2025.
- Its last three reported values are $125.2 million in Q3 2025, $79.1 million for Q2 2025, and $40.3 million during Q1 2025.